Russell Midcap Index

Nissin Foods Becomes Eligible Trading Stock under Shanghai-Hong Kong Stock Connect

Retrieved on:

Sunday, March 12, 2023

Nissin Foods, Russell Midcap Index, Shanghai Stock Exchange, Shanghai-Hong Kong Stock Connect, Hang Seng Composite Index Series, Film industry, Southbound

HONG KONG, Mar 13, 2023 - (ACN Newswire) - Nissin Foods Company Limited ("Nissin Foods", and together with its subsidiaries, the "Group"; Stock code: 1475) will become a new eligible stock for trading under the Shanghai-Hong Kong Stock Connect, effective today, 13 March 2023, in accordance with the latest expansion of the scope of eligible stocks under the Stock Connect scheme as announced by the Shanghai Stock Exchange.

Key Points:

HONG KONG, Mar 13, 2023 - (ACN Newswire) - Nissin Foods Company Limited ("Nissin Foods", and together with its subsidiaries, the "Group"; Stock code: 1475) will become a new eligible stock for trading under the Shanghai-Hong Kong Stock Connect, effective today, 13 March 2023, in accordance with the latest expansion of the scope of eligible stocks under the Stock Connect scheme as announced by the Shanghai Stock Exchange.
The Shanghai-Hong Kong Stock Connect was officially launched in 2014 with the aim of establishing mutual stock market access between Mainland China and Hong Kong.
The stock connect allows qualified investors in Mainland China to access eligible Hong Kong shares (Southbound) as well as Hong Kong and overseas investors to trade eligible A shares (Northbound) subject to a certain amount of daily quota.
Being included in Shanghai-Hong Kong Stock Connect is a major milestone in our corporate development, indicating that Nissin Foods will be accessible to more traders in Mainland China through the Shanghai and Shenzhen Stock Connect which the Group earned inclusion earlier.

Valbiotis Provides an Update on Its Progress and Publishes Its Financial Report for the First Half of 2022

Retrieved on:

Thursday, September 15, 2022

In July 2022, Valbiotis announced the end of recruitment with the randomization of the last of the 600 participating volunteers ( press release of July 28, 2022 ).

Key Points:

In July 2022, Valbiotis announced the end of recruitment with the randomization of the last of the 600 participating volunteers ( press release of July 28, 2022 ).
In February 2022, Valbiotis received approval to initiate two Phase II/III clinical trials, INSIGHT and INSIGHT 2 ( press release of February 17, 2022 ).
The Company's interim financial statements, prepared in accordance with IFRS, were approved by the Board of Directors on September 7, 2022.
They have been subject to a limited review by the Statutory Auditor and are available on the Valbiotis website: www.valbiotis.com (investors section).

China Risun's 2022 Interim Revenue Ups 21.1% to RMB22.53 Billion, Profit Attributable to Owners was RMB1.74 Billion

Retrieved on:

Monday, August 29, 2022

Revenue for the six months ended June 30, 2022 was approximately RMB22.53 billion, representing an increase of approximately 21.1%.

Key Points:

Revenue for the six months ended June 30, 2022 was approximately RMB22.53 billion, representing an increase of approximately 21.1%.
Profit attributable to owners of the Company was approximately RMB1.74 billion, up approximately 0.8%.
During the reporting period, revenue derived from the coke and coking chemicals manufacturing business continued to increase, up 20.2% to RMB9,262.7 million.
China Risun is also included in FTSE GEIS: FTSE Global Small Cap Index, FTSE Global All-Cap Index (LMS) and FTSE Global Total-Cap Index (LMSu).

Sino Biopharmaceutical (1177.HK) Announces 2022 lnterim Results, Revenue up by 5.9% to RMB15.19 billion

Retrieved on:

Tuesday, August 23, 2022

-- Focus V (Anlotinib Hydrochloride Capsules) was approved for the fifth indication-differentiated thyroid cancer in the first half of 2022.

Key Points:

-- Focus V (Anlotinib Hydrochloride Capsules) was approved for the fifth indication-differentiated thyroid cancer in the first half of 2022.
During the Period, the Group recorded revenue of approximately RMB15.19 billion, an increase of approximately 5.9% against last year.
Sales of oncology medicines increased by 16.7% year-on-year to approximately 4.96 billion, accounting for approximately 32.6% of the Group's revenue.
Sino Biopharmaceutical Limited is a leading, innovative R&D-driven pharmaceutical conglomerate in the PRC.

China Risun's 2021 Annual Profit Attributable to Owners Ups 58.1% to RMB2.61 billion

Retrieved on:

Monday, March 28, 2022

Profit attributable to owners up 58.1% to RMB2.61 billion, achieving a 3-year consecutive growth since its listing in 2019.

Key Points:

Profit attributable to owners up 58.1% to RMB2.61 billion, achieving a 3-year consecutive growth since its listing in 2019.
Revenue for the year ended 31 December 2021 was RMB38.4 billion, representing an increase of 94.2% year-on-year.
In 2021, the price of coke reached a record high in China, and the profitability of the industry continued to improve.
As the core profit source of China Risun, the coke business performed very well.

Valbiotis is Strengthening Its Commitment to CSR by Joining the United Nations Global Compact and Applying the ISO 26000 Standard

Retrieved on:

Tuesday, March 22, 2022

Valbiotis (Paris:ALVAL) (FR0013254851 - ALVAL, eligible for PEA / SME), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, is strengthening its commitment to Corporate Social Responsibility (CSR) by joining the United Nations Global Compact and applying the ISO 26000 standard.

Key Points:

Valbiotis (Paris:ALVAL) (FR0013254851 - ALVAL, eligible for PEA / SME), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, is strengthening its commitment to Corporate Social Responsibility (CSR) by joining the United Nations Global Compact and applying the ISO 26000 standard.
The United Nations Global Compact brings together businesses, organizations, UN agencies, the professional world and civil society around 10 universally accepted principles to build more stable and inclusive societies.
Valbiotis, through its membership, supports the 10 principles of the United Nations Global Compact concerning the respect for human rights, international labor standards, environmental protections and the fight against corruption.
Valbiotis will also participate in projects advancing the broader development goals of the United Nations, in particular contributing to the achievement of the Sustainable Development Goals (SDGs).

IndexIQ Introduces ETF Suite Focused on Leaders in Research & Development

Retrieved on:

Tuesday, February 8, 2022

The R&D ETF suite joins a multi-asset family of cutting-edge ETFs from IndexIQ that includes the IQ Hedge Multi-Strategy ETF (QAI), the first liquid alternative ETF; innovative fixed income offerings like the IQ MacKay ESG Core Plus Bond ETF (ESGB); and the firms Dual Impact ETF suite, which includes IQ Healthy Hearts ETF (HART), IQ Engender Equality ETF (EQUL), IQ Cleaner Transport ETF (CLNR), and IQ Clean Oceans ETF (OCEN).

Key Points:

The R&D ETF suite joins a multi-asset family of cutting-edge ETFs from IndexIQ that includes the IQ Hedge Multi-Strategy ETF (QAI), the first liquid alternative ETF; innovative fixed income offerings like the IQ MacKay ESG Core Plus Bond ETF (ESGB); and the firms Dual Impact ETF suite, which includes IQ Healthy Hearts ETF (HART), IQ Engender Equality ETF (EQUL), IQ Cleaner Transport ETF (CLNR), and IQ Clean Oceans ETF (OCEN).
Mid Cap R&D Leaders Index, IQ U.S. Large Cap R&D Leaders Index and IQ Global Equity R&D Leaders Index, respectively.
Mid Cap R&D Leaders ETF, IQ U.S. Large Cap R&D Leaders ETF and IQ Global Equity R&D Leaders ETF.
Mid Cap R&D Leaders Index, IQ U.S. Large Cap R&D Leaders Index and IQ Global Equity R&D Leaders Index.

KWIH Announces 2021 Interim Results, Total Attributable Contracted Sales to be Recognised Reaches HK$17.4 Billion

Retrieved on:

Tuesday, August 24, 2021

For the six months ended 30 June 2021, the Group's attributable contracted sales amounted to approximately HK$9.6 billion.

Key Points:

For the six months ended 30 June 2021, the Group's attributable contracted sales amounted to approximately HK$9.6 billion.
As at the end of June 2021, total attributable contracted sales yet to be recognised amounted to approximately HK$17.4 billion, which are expected to be accounted for in the second half of 2021 and 2022, underpinning the Group's future profitability.
As of the end of June 2021, more than 960 units, which accounted for over 95% of the total, were sold with a total contracted sales of approximately HK$10.9 billion.
All units were taken up on the day of its debut, with a total sales amount of approximately RMB2.4 billion.

Ocwen Financial Announces Inclusion in the Russell 2000® Index

Russell Indexes, Finance, Money, Investment management, Index fund, Russell 2000 Index, Russell 3000 Index, Active management, FTSE Russell, Russell Midcap Index, Russell 2500 Index

Membership in the Russell 2000 Index means automatic inclusion in the broader Russell 3000 Index as well as in the appropriate growth and value style indexes.

Key Points:

Membership in the Russell 2000 Index means automatic inclusion in the broader Russell 3000 Index as well as in the appropriate growth and value style indexes.
The Russell 3000 Index encompasses the 3,000 largest US-traded stocks primarily by objective, market-capitalization rankings and style attributes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
For more information on the Russell indexes and the Russell indexes reconstitution, visit the FTSE Russell website .

Creatd Set to be Added to Russell Microcap® Index

Retrieved on:

Monday, June 7, 2021

Russell Indexes, London Stock Exchange, Russell Microcap Index, Stock market indices, FTSE Russell, Index, Russell, FTSE, Economic data, Index numbers, Russell 2500 Index, Russell Midcap Index

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in Russell's appropriate growth and value style indexes.

Key Points:

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in Russell's appropriate growth and value style indexes.
FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.
For more information on the Russell Microcap Index and the Russell indexes reconstitution, please refer to the "Russell Reconstitution" section on the FTSE Russell website .
A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants.